Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Trigemina, Inc. logo — Creating innovative non-opiate drug formulations and deliver...

Trigemina, Inc.

Creating innovative non-opiate drug formulations and delivery systems for effective pain relief.

Founded 2006 3 employees Series A Total: $27.60M Biotechnology

General Information

Company Name Trigemina, Inc.
Founded Year 2006
Founders / Decision Makers
Team member
Employees 3
Industries Biotechnology
Funding Stage Series A
Social

Get notified when Trigemina, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Trigemina, Inc.

Trigemina, Inc. is a biotechnology startup founded in 2006. Their mission revolves around creating innovative non-opiate drug formulations and delivery systems for effective pain relief. The company's slogan, "Creating innovative non-opiate drug formulations and delivery systems for effective pain relief," encapsulates their focus on developing novel, non-opioid, non-sedating, cognition-neutral neurological therapies. Trigemina aims to utilize their innovative naso-cerebral delivery systems for the relief of chronic migraine and other neuropathic pain. The company received a significant $2.40M Series A investment on 15 July 2017 to further their groundbreaking work in this field. Although details about the investors involved in the last investment round are not specified, this influx of funds likely bolstered Trigemina's research and development efforts. Overall, Trigemina, Inc. stands at the forefront of developing cutting-edge solutions for chronic pain management, with a focus on non-opioid, non-sedating drug formulations and innovative delivery systems. Given the ongoing concerns surrounding opioid-based treatments, Trigemina's commitment to pioneering non-opiate therapies makes them an intriguing prospect for venture capital consideration.

Taxonomy: non-opiate drugs, drug formulations, pain relief, delivery systems, intranasal drug delivery, oxytocin therapy, chronic pain treatment, neuropathic pain, pharmaceutical company, innovative treatments, healthcare innovations

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• - 15 Jul 2017
Series A •••••• - 01 Jun 2015
Venture Round •••••• 1
Investor
14 Apr 2014
Series A •••••• - 13 Jun 2013
Venture Round •••••• - 18 Oct 2010

View All 7 Funding Rounds

Trigemina, Inc. Alternatives & Competitors

Trigemina, Inc. vs
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. United States

Our mission is to dramatically improve the lives of patients by developing breakthrough non-opioid p...

Convertible Note
19 employees
Biotechnology, Health Care
Trigemina, Inc. vs
Chromocell Therapeutics Corporation
Chromocell Therapeutics Corporation United States

Breakthroughs that break through pain and addiction

30 employees
Biotechnology
Trigemina, Inc. vs
Palyon Medical Corporation
Palyon Medical Corporation

Innovative solutions for chronic pain, spasticity, and neurological diseases

Series A
1 employees
Health Care, Medical Devices

FAQ About Trigemina, Inc.

Creating innovative non-opiate drug formulations and delivery systems for effective pain relief.
Trigemina, Inc. was founded in 2006.
Trigemina, Inc. operates in the following industries: Biotechnology.
Trigemina, Inc. has approximately 3 employees.
Trigemina, Inc. has completed 7 funding rounds, raising a total of $27.60M. The latest funding stage is Series A.
Top alternatives and competitors to Trigemina, Inc. include Concentric Analgesics, Inc., Chromocell Therapeutics Corporation, Palyon Medical Corporation, Akelos Inc, Scilex Holding Company. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Trigemina, Inc. and Concentric Analgesics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Trigemina, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy